Mathai Mammen is the Chairman, CEO and President of Parabilis Medicines (formerly FogPharma), a Cambridge biotech going after cancer targets long written off as undruggable. A trained physician-chemist who co-founded Theravance out of grad school and later ran R&D at Merck and Johnson & Johnson, he has had a hand in the discovery or development of roughly 19 approved medicines. At Parabilis he is betting on Helicon peptides - engineered molecules that slip inside cells to hit protein-protein interfaces small molecules and antibodies cannot reach.
Rick Winningham is the CEO of Theravance Biopharma, a biopharmaceutical company focused on organ-selective medicines for serious diseases including COPD, rare neurological conditions, and inflammatory diseases. With over 40 years in the pharmaceutical industry - including 13 years as CEO of Innoviva and 15 years at Bristol-Myers Squibb - Winningham has built a career defined by transformative drug development, strategic company leadership, and a widely recognized commitment to mentoring the next generation of biopharma executives, particularly women in leadership. He was named the 2026 HBA Honorable Mentor by the Healthcare Businesswomen's Association.